X

Trial Profile

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rintatolimod (Primary)
Indications Chronic fatigue syndrome; Encephalomyelitis
Focus Expanded access; Therapeutic Use
Sponsors AIM ImmunoTech

Most Recent Events

15 Nov 2022 According to an AIM ImmunoTech media release, the company has enrolled five post-COVID patients with new onset ME/CFS following acute COVID-19.
28 Jul 2022 Interim results published in an AIM ImmunoTech Media Release.
18 May 2022 Results presented in an AIM ImmunoTech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com